Pfizer PFE will report its first-quarter earnings on April 29, before market open. The Zacks Consensus Estimate for sales and ...

Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 ...

Pfizer Inc.'s stock is trading at $22 with an 8% dividend yield, driven by market fears over losing vaccine revenues. Read ...

Pfizer Inc. (NYSE: PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American Society of Clinical ...

As tough as it may be to do right now, this is a great time to hold your nose and dive in while yields are as high as they ...

Pfizer (PFE) will showcase data across its portfolio of potential breakthrough cancer medicines at the 2025 American ...

highlight advancements across Pfizer’s industry-leading Oncology portfolio ASCO press program to feature overall survival and progression-free survival data for BRAFTOVI® (encorafenib ...

Sales of Xtandi, Lorbrena and Braftovi/Mektovi are likely to have increased. The antibody-drug conjugates or ADCs — Adcetris, Padcev, Tukysa and Tivdak — added to Pfizer’s portfolio with the ...

Pfizer Oncology. “Important early-stage updates highlight our extensive pipeline and depth within our core cancer types, as we advance up to nine new pivotal phase 3 trials this year.” Key ASCO ...